Can lisinopril (angiotensin‑converting‑enzyme inhibitor) cause spots or rash on the legs?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Lisinopril Cause Spots on Legs?

Yes, lisinopril can cause spots or rash on the legs, though this is an uncommon adverse effect that occurs in approximately 2% of patients, with more serious cutaneous reactions like vasculitis being rare.

Spectrum of Cutaneous Reactions to Lisinopril

ACE inhibitors like lisinopril are associated with a broad range of skin manifestations. The overall incidence of adverse effects to ACE inhibitors is estimated at 28%, with approximately half occurring in the skin 1. These cutaneous reactions can mimic various skin diseases and should be considered when sudden, unexplainable skin eruptions appear 1.

Common Cutaneous Manifestations

The skin reactions associated with lisinopril include:

  • Generalized rashes affecting various body parts including the legs, occurring in approximately 2% of patients 2
  • Pruritus (itching), which can affect up to 15% of patients taking ACE inhibitors 2
  • Urticaria (hives) 1
  • Photosensitivity reactions 1
  • Bullous eruptions (blistering) 1

Serious Cutaneous Reactions

More concerning reactions that can present with spots or lesions on the legs include:

  • Cutaneous vasculitis: This presents as a painful, symmetrical purpuric (purple-red spots) eruption, often affecting the feet and lower legs 3. While rare, this can develop within days of starting the medication and may require steroid therapy 3.
  • Angioedema: Though typically affecting the face and lips, this life-threatening reaction occurs in fewer than 1% of patients and is more frequent in Black patients 4, 5

Clinical Evaluation Approach

When evaluating spots on the legs in a patient taking lisinopril, look for:

  • Timing: Drug-induced rashes typically develop within days to weeks after starting medication 6
  • Distribution: Note whether the rash is symmetrical and whether it affects both legs 3
  • Characteristics: Determine if the spots are purpuric (non-blanching), urticarial (raised, itchy), or photodistributed 1
  • Associated symptoms: Assess for pain, pruritus, or systemic symptoms 3

Management Strategy

For Mild Rash

  • Continue lisinopril with close monitoring if the rash is mild and non-progressive 6
  • Consider topical therapies such as moisturizers or low-potency corticosteroids 6
  • Rule out other causes of rash before attributing to lisinopril 1

For Moderate to Severe Rash

  • Temporarily discontinue lisinopril if the rash is progressive, painful, or accompanied by systemic symptoms 6, 3
  • Perform a full vasculitis workup if purpuric lesions are present 3
  • Consider systemic corticosteroids for significant reactions, particularly vasculitis 3
  • If the rash resolves, rechallenge may be attempted at a lower dose with careful monitoring, though this should be avoided if vasculitis was confirmed 6

For Life-Threatening Reactions

  • Permanently discontinue lisinopril if angioedema or bullous/exfoliative eruptions occur 4, 5, 1
  • Do not rechallenge with any ACE inhibitor if angioedema has occurred 4, 5
  • Exercise extreme caution when substituting an ARB, as cross-reactivity can occur 4, 5

Important Clinical Caveats

Previous tolerance does not guarantee future safety: A patient who previously tolerated one ACE inhibitor (like lisinopril) can still develop cutaneous vasculitis with another ACE inhibitor from the same class 3. This means that prior successful treatment with lisinopril does not rule out future adverse cutaneous reactions.

Consider alternative causes: Before attributing skin lesions to lisinopril, exclude other common causes such as venous stasis dermatitis, contact dermatitis, or other concurrent medications 1.

Risk factors for cutaneous reactions include higher doses, drug interactions (particularly with CYP3A4 inhibitors), dehydration, and concurrent use of other medications 7, 6.

Related Questions

Which blood pressure medications are known to cause itching?
Can lisinopril cause thinning of the skin and increased bleeding?
A 31-year-old patient has been taking lisinopril 30 mg daily for hypertension for two weeks; morning blood pressure is approximately 110/65 mmHg and evening blood pressure is 135/70‑80 mmHg, with a target ≤130/80 mmHg. What is the next step in blood pressure management?
Should the lisinopril dose be decreased when adding daily Cialis (tadalafil) to avoid hypotension?
For a 42-year-old healthy male on lisinopril, bupropion (Wellbutrin), and sildenafil with serum creatinine 1.32 mg/dL, what dosing adjustments or monitoring are recommended?
Is retatrutide approved for routine clinical use in any country?
How does Capmist DM (dextromethorphan 15 mg, guaifenesin 400 mg, pseudoephedrine 30 mg) compare to a pseudoephedrine‑guaifenesin (pseudoephedrine 30 mg, guaifenesin 400 mg) product for an adult needing cough and congestion relief?
How do postoperative sensations differ between internal anal sphincter hypertonicity and nerve injury or scar‑related sensory alteration after hemorrhoidectomy?
Can doxycycline be used as monotherapy for typical cellulitis, or should it be combined with a beta‑lactam antibiotic for streptococcal coverage, especially in patients at risk for community‑associated methicillin‑resistant Staphylococcus aureus (MRSA)?
What is the recommended initial work‑up for a patient with suspected olecranon bursitis?
What insulin dose should be used in the total parenteral nutrition (TPN) when a 24‑hour infusion of 170 g dextrose with 15 units insulin is changed to an 18‑hour infusion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.